Co-morbid Polycystic Ovarian Syndrome with Idiopathic Intracranial Hypertension

Overview

Journal Neuroophthalmology

Specialty Neurology

Date 2023 Feb 17

PMID 36798860

Authors

Mark Thaller

Nicola J Adderley

Anuradhaa Subramanian

Susan P Mollan

Alexandra J Sinclair

Affiliations

Soon will be listed here.

Abstract

The link between polycystic ovarian syndrome (PCOS) and idiopathic intracranial hypertension (IIH) has long been debated. Historically, there is a wide range of reported occurrence of both conditions, being between 15% and 64%. Both conditions share a common phenotype. The awareness that in a new large data study that there is a 1.5-fold increased prevalence of diagnosed PCOS in participants with IIH as compared to the controls is important. Assessment for the potential of co-morbid PCOS in women with IIH is important as this may enable optimisation of weight and fertility management.

Citing Articles

Longitudinal visual outcomes in idiopathic intracranial hypertension: the role of early prognostic indicators and risk stratification in disease management.

Colman B, Sanfilippo P, Fok A, Le Nguyen M, Kini R, Chakrabarti R J Neurol. 2025; 272(2):108.

PMID: 39812855 DOI: 10.1007/s00415-024-12859-3.

Cardiometabolic Outcomes in Idiopathic Intracranial Hypertension: An International Matched-Cohort Study.

Azzam A, Essibayi M, Vaishnav D, Morsy M, Elamin O, Al Zomia A medRxiv. 2024; .

PMID: 39677466 PMC: 11643231. DOI: 10.1101/2024.11.12.24317203.

Managing idiopathic intracranial hypertension in the eye clinic.

Bonelli L, Menon V, Arnold A, Mollan S Eye (Lond). 2024; 38(12):2472-2481.

PMID: 38789788 PMC: 11306398. DOI: 10.1038/s41433-024-03140-y.

Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms.

Yiangou A, Mollan S, Sinclair A Nat Rev Neurol. 2023; 19(12):769-785.

PMID: 37957260 DOI: 10.1038/s41582-023-00893-0.

Longitudinal prospective cohort study evaluating prognosis in idiopathic intracranial hypertension patients with and without comorbid polycystic ovarian syndrome.

Thaller M, Homer V, Sassani M, Mollan S, Sinclair A Eye (Lond). 2023; 37(17):3621-3628.

PMID: 37225826 PMC: 10686374. DOI: 10.1038/s41433-023-02569-x.

References

Teede H, Misso M, Costello M, Dokras A, Laven J, Moran L . Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018; 89(3):251-268. PMC: 9052397. DOI: 10.1111/cen.13795. View

Kempegowda P, Melson E, Manolopoulos K, Arlt W, OReilly M . Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2020; 11:2042018820934319. PMC: 7315669. DOI: 10.1177/2042018820934319. View

Ghandi S, Aflatoonian A, Tabibnejad N, Moghaddam M . The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. J Assist Reprod Genet. 2011; 28(7):591-6. PMC: 3162050. DOI: 10.1007/s10815-011-9564-2. View

Thaller M, Homer V, Hyder Y, Yiangou A, Liczkowski A, Fong A . The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes. J Neurol. 2022; 270(2):851-863. PMC: 9886634. DOI: 10.1007/s00415-022-11402-6. View

Mollan S, Wakerley B, Alimajstorovic Z, Mitchell J, Ottridge R, Yiangou A . Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension. J Headache Pain. 2021; 22(1):118. PMC: 8499560. DOI: 10.1186/s10194-021-01321-8. View

Graff S, Mario F, Ziegelmann P, Spritzer P . Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. Int J Clin Pract. 2016; 70(6):450-61. DOI: 10.1111/ijcp.12787. View

Mollan S, Mitchell J, Ottridge R, Aguiar M, Yiangou A, Alimajstorovic Z . Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension: A Randomized Clinical Trial. JAMA Neurol. 2021; 78(6):678-686. PMC: 8077040. DOI: 10.1001/jamaneurol.2021.0659. View

OReilly M, Westgate C, Hornby C, Botfield H, Taylor A, Markey K . A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight. 2019; 4(6). PMC: 6483000. DOI: 10.1172/jci.insight.125348. View

Balen A, Morley L, Misso M, Franks S, Legro R, Wijeyaratne C . The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance. Hum Reprod Update. 2016; 22(6):687-708. DOI: 10.1093/humupd/dmw025. View

10.

Mollan S, Grech O, Alimajstorovic Z, Wakerley B, Sinclair A . New horizons for idiopathic intracranial hypertension: advances and challenges. Br Med Bull. 2020; 136(1):118-126. DOI: 10.1093/bmb/ldaa034. View

11.

Thaller M, Mytton J, Wakerley B, Mollan S, Sinclair A . Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset. BJOG. 2022; 129(12):2019-2027. PMC: 9796176. DOI: 10.1111/1471-0528.17241. View

12.

Adderley N, Subramanian A, Perrins M, Nirantharakumar K, Mollan S, Sinclair A . Headache, Opiate Use, and Prescribing Trends in Women With Idiopathic Intracranial Hypertension: A Population-Based Matched Cohort Study. Neurology. 2022; 99(18):e1968-e1978. PMC: 9651462. DOI: 10.1212/WNL.0000000000201064. View

13.

Hornby C, Mollan S, Botfield H, OReilly M, Sinclair A . Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. J Neuroophthalmol. 2018; 38(4):522-530. PMC: 6215484. DOI: 10.1097/WNO.0000000000000684. View

14.

Grech O, Sassani M, Terwindt G, Lavery G, Mollan S, Sinclair A . Alterations in metabolic flux in migraine and the translational relevance. J Headache Pain. 2022; 23(1):127. PMC: 9523955. DOI: 10.1186/s10194-022-01494-w. View

15.

Glueck C, Iyengar S, Goldenberg N, Smith L, Wang P . Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med. 2003; 142(1):35-45. DOI: 10.1016/S0022-2143(03)00069-6. View

16.

Avisar I, Gaton D, Dania H, Stiebel-Kalish H . The prevalence of polycystic ovary syndrome in women with idiopathic intracranial hypertension. Scientifica (Cairo). 2013; 2012:708042. PMC: 3820517. DOI: 10.6064/2012/708042. View

17.

Grech O, Seneviratne S, Alimajstorovic Z, Yiangou A, Mitchell J, Smith T . Nuclear Magnetic Resonance Spectroscopy Metabolomics in Idiopathic Intracranial Hypertension to Identify Markers of Disease and Headache. Neurology. 2022; 99(16):e1702-e1714. PMC: 9620805. DOI: 10.1212/WNL.0000000000201007. View

18.

Cho L, Kilpatrick E, Keevil B, Coady A, Atkin S . Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008; 70(2):233-7. DOI: 10.1111/j.1365-2265.2008.03309.x. View

19.

Mollan S, Mitchell J, Yiangou A, Ottridge R, Alimajstorovic Z, Cartwright D . Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension. Neurology. 2022; 99(11):e1090-e1099. PMC: 9536743. DOI: 10.1212/WNL.0000000000200839. View

20.

Subramanian A, Lee S, Phillips K, Toulis K, Kempegowda P, OReilly M . Polycystic ovary syndrome and risk of adverse obstetric outcomes: a retrospective population-based matched cohort study in England. BMC Med. 2022; 20(1):298. PMC: 9425992. DOI: 10.1186/s12916-022-02473-3. View